Our news

ARTICLE ABOUT 2A PHARMA IN MEDWATCH

The following article was published in Danish pharma industry publication MedWatch on 16 January 2017.

READ MORE

EXCLUSIVE WORLDWIDE LICENSE AGREEMENT

Medigene AG today announced that it has granted an exclusive, worldwide license for the development and commercialization of its preclinical stage adeno-associated virus-like particles (AAVLPs) technology to 2A Pharma AB.

[pdf-embedder url="https://2apharma.com/wp-content/uploads/2016/12/Proposal-web-related-2A-Pharma..pdf"]
READ MORE

FIRST FINANCING ROUND CLOSED

2A Pharma AB today closed its first financing round, raising SEK 27 million from private angel investors. This new capital will enable us to take our first project, the AAVLP-HPV vaccine, through tothe end of phase I clinical studies. We are grateful for our investors’ support and trust.
...

READ MORE

2A PHARMA IS A REALITY

2A Pharma AB was incorporated in Sweden on 12 December 2016.

Søren Nielsen, CEO: “This marks the formal beginning of a new exciting venture and the team is very excited about the journey ahead.”

READ MORE